Literature DB >> 32430477

CD8+ T-cell-Mediated Immunoediting Influences Genomic Evolution and Immune Evasion in Murine Gliomas.

Joshua R Kane1, Junfei Zhao2,3, Takashi Tsujiuchi4, Brice Laffleur5, Víctor A Arrieta1,6, Aayushi Mahajan4, Ganesh Rao7, Angeliki Mela8, Crismita Dmello1, Li Chen1, Daniel Y Zhang1, Edgar González-Buendia1, Catalina Lee-Chang1, Ting Xiao1, Gerson Rothschild5, Uttiya Basu5, Craig Horbinski1, Maciej S Lesniak1, Amy B Heimberger7, Raul Rabadan2,3,9, Peter Canoll8, Adam M Sonabend10.   

Abstract

PURPOSE: Cancer immunoediting shapes tumor progression by the selection of tumor cell variants that can evade immune recognition. Given the immune evasion and intratumor heterogeneity characteristic of gliomas, we hypothesized that CD8+ T cells mediate immunoediting in these tumors. EXPERIMENTAL
DESIGN: We developed retrovirus-induced PDGF+ Pten -/- murine gliomas and evaluated glioma progression and tumor immunogenicity in the absence of CD8+ T cells by depleting this immune cell population. Furthermore, we characterized the genomic alterations present in gliomas that developed in the presence and absence of CD8+ T cells.
RESULTS: Upon transplantation, gliomas that developed in the absence of CD8+ T cells engrafted poorly in recipients with intact immunity but engrafted well in those with CD8+ T-cell depletion. In contrast, gliomas that developed under pressure from CD8+ T cells were able to fully engraft in both CD8+ T-cell-depleted mice and immunocompetent mice. Remarkably, gliomas developed in the absence of CD8+ T cells exhibited increased aneuploidy, MAPK pathway signaling, gene fusions, and macrophage/microglial infiltration, and showed a proinflammatory phenotype. MAPK activation correlated with macrophage/microglia recruitment in this model and in the human disease.
CONCLUSIONS: Our studies indicate that, in these tumor models, CD8+ T cells influence glioma oncogenic pathways, tumor genotype, and immunogenicity. This suggests immunoediting of immunogenic tumor clones through their negative selection by CD8+ T cells during glioma formation. ©2020 American Association for Cancer Research.

Entities:  

Year:  2020        PMID: 32430477      PMCID: PMC7442699          DOI: 10.1158/1078-0432.CCR-19-3104

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  47 in total

1.  NetMHCcons: a consensus method for the major histocompatibility complex class I predictions.

Authors:  Edita Karosiene; Claus Lundegaard; Ole Lund; Morten Nielsen
Journal:  Immunogenetics       Date:  2011-10-20       Impact factor: 2.846

Review 2.  Cancer Neoantigens and Applications for Immunotherapy.

Authors:  Alexis Desrichard; Alexandra Snyder; Timothy A Chan
Journal:  Clin Cancer Res       Date:  2015-10-29       Impact factor: 12.531

3.  Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma.

Authors:  Anoop P Patel; Itay Tirosh; John J Trombetta; Alex K Shalek; Shawn M Gillespie; Hiroaki Wakimoto; Daniel P Cahill; Brian V Nahed; William T Curry; Robert L Martuza; David N Louis; Orit Rozenblatt-Rosen; Mario L Suvà; Aviv Regev; Bradley E Bernstein
Journal:  Science       Date:  2014-06-12       Impact factor: 47.728

4.  Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial.

Authors:  Roger Stupp; Sophie Taillibert; Andrew Kanner; William Read; David Steinberg; Benoit Lhermitte; Steven Toms; Ahmed Idbaih; Manmeet S. Ahluwalia; Karen Fink; Francesco Di Meco; Frank Lieberman; Jay-Jiguang Zhu; Giuseppe Stragliotto; David Tran; Steven Brem; Andreas Hottinger; Eilon D. Kirson; Gitit Lavy-Shahaf; Uri Weinberg; Chae-Yong Kim; Sun-Ha Paek; Garth Nicholas; Jordi Bruna; Hal Hirte; Michael Weller; Yoram Palti; Monika E. Hegi; Zvi Ram
Journal:  JAMA       Date:  2017-12-19       Impact factor: 56.272

Review 5.  Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion.

Authors:  Robert D Schreiber; Lloyd J Old; Mark J Smyth
Journal:  Science       Date:  2011-03-25       Impact factor: 47.728

Review 6.  Mitogen-activated protein kinases in innate immunity.

Authors:  J Simon C Arthur; Steven C Ley
Journal:  Nat Rev Immunol       Date:  2013-08-19       Impact factor: 53.106

7.  Predictive screening of M1 and M2 macrophages reveals the immunomodulatory effectiveness of post spinal cord injury azithromycin treatment.

Authors:  John C Gensel; Timothy J Kopper; Bei Zhang; Michael B Orr; William M Bailey
Journal:  Sci Rep       Date:  2017-01-06       Impact factor: 4.379

Review 8.  The M1 and M2 paradigm of macrophage activation: time for reassessment.

Authors:  Fernando O Martinez; Siamon Gordon
Journal:  F1000Prime Rep       Date:  2014-03-03

Review 9.  The possibility of cancer immune editing in gliomas. A critical review.

Authors:  Víctor A Arrieta; Bernardo Cacho-Díaz; Junfei Zhao; Raul Rabadan; Li Chen; Adam M Sonabend
Journal:  Oncoimmunology       Date:  2018-04-09       Impact factor: 8.110

10.  Longitudinal molecular trajectories of diffuse glioma in adults.

Authors:  Floris P Barthel; Kevin C Johnson; Frederick S Varn; Anzhela D Moskalik; Georgette Tanner; Emre Kocakavuk; Kevin J Anderson; Olajide Abiola; Kenneth Aldape; Kristin D Alfaro; Donat Alpar; Samirkumar B Amin; David M Ashley; Pratiti Bandopadhayay; Jill S Barnholtz-Sloan; Rameen Beroukhim; Christoph Bock; Priscilla K Brastianos; Daniel J Brat; Andrew R Brodbelt; Alexander F Bruns; Ketan R Bulsara; Aruna Chakrabarty; Arnab Chakravarti; Jeffrey H Chuang; Elizabeth B Claus; Elizabeth J Cochran; Jennifer Connelly; Joseph F Costello; Gaetano Finocchiaro; Michael N Fletcher; Pim J French; Hui K Gan; Mark R Gilbert; Peter V Gould; Matthew R Grimmer; Antonio Iavarone; Azzam Ismail; Michael D Jenkinson; Mustafa Khasraw; Hoon Kim; Mathilde C M Kouwenhoven; Peter S LaViolette; Meihong Li; Peter Lichter; Keith L Ligon; Allison K Lowman; Tathiane M Malta; Tali Mazor; Kerrie L McDonald; Annette M Molinaro; Do-Hyun Nam; Naema Nayyar; Ho Keung Ng; Chew Yee Ngan; Simone P Niclou; Johanna M Niers; Houtan Noushmehr; Javad Noorbakhsh; D Ryan Ormond; Chul-Kee Park; Laila M Poisson; Raul Rabadan; Bernhard Radlwimmer; Ganesh Rao; Guido Reifenberger; Jason K Sa; Michael Schuster; Brian L Shaw; Susan C Short; Peter A Sillevis Smitt; Andrew E Sloan; Marion Smits; Hiromichi Suzuki; Ghazaleh Tabatabai; Erwin G Van Meir; Colin Watts; Michael Weller; Pieter Wesseling; Bart A Westerman; Georg Widhalm; Adelheid Woehrer; W K Alfred Yung; Gelareh Zadeh; Jason T Huse; John F De Groot; Lucy F Stead; Roel G W Verhaak
Journal:  Nature       Date:  2019-11-20       Impact factor: 69.504

View more
  14 in total

1.  Anti-PD-1 Induces M1 Polarization in the Glioma Microenvironment and Exerts Therapeutic Efficacy in the Absence of CD8 Cytotoxic T Cells.

Authors:  Ganesh Rao; Khatri Latha; Martina Ott; Aria Sabbagh; Anantha Marisetty; Xiaoyang Ling; Daniel Zamler; Tiffany A Doucette; Yuhui Yang; Ling-Yuan Kong; Jun Wei; Gregory N Fuller; Fernando Benavides; Adam M Sonabend; James Long; Shulin Li; Michael Curran; Amy B Heimberger
Journal:  Clin Cancer Res       Date:  2020-06-18       Impact factor: 12.531

Review 2.  Emerging immunotherapies for malignant glioma: from immunogenomics to cell therapy.

Authors:  Gavin P Dunn; Timothy F Cloughesy; Marcela V Maus; Robert M Prins; David A Reardon; Adam M Sonabend
Journal:  Neuro Oncol       Date:  2020-10-14       Impact factor: 12.300

3.  TOP2B Enzymatic Activity on Promoters and Introns Modulates Multiple Oncogenes in Human Gliomas.

Authors:  Edgar Gonzalez-Buendia; Junfei Zhao; Lu Wang; Subhas Mukherjee; Daniel Zhang; Víctor A Arrieta; Eric Feldstein; J Robert Kane; Seong Jae Kang; Catalina Lee-Chang; Aayushi Mahajan; Li Chen; Ronald Realubit; Charles Karan; Lisa Magnuson; Craig Horbinski; Stacy A Marshall; Jann N Sarkaria; Ahmed Mohyeldin; Ichiro Nakano; Mukesh Bansal; Charles D James; Daniel J Brat; Atique Ahmed; Peter Canoll; Raul Rabadan; Ali Shilatifard; Adam M Sonabend
Journal:  Clin Cancer Res       Date:  2021-08-25       Impact factor: 12.531

4.  Glioma progression is shaped by genetic evolution and microenvironment interactions.

Authors:  Frederick S Varn; Kevin C Johnson; Jan Martinek; Jason T Huse; MacLean P Nasrallah; Pieter Wesseling; Lee A D Cooper; Tathiane M Malta; Taylor E Wade; Thais S Sabedot; Daniel Brat; Peter V Gould; Adelheid Wöehrer; Kenneth Aldape; Azzam Ismail; Santhosh K Sivajothi; Floris P Barthel; Hoon Kim; Emre Kocakavuk; Nazia Ahmed; Kieron White; Indrani Datta; Hyo-Eun Moon; Steven Pollock; Christine Goldfarb; Ga-Hyun Lee; Luciano Garofano; Kevin J Anderson; Djamel Nehar-Belaid; Jill S Barnholtz-Sloan; Spyridon Bakas; Annette T Byrne; Fulvio D'Angelo; Hui K Gan; Mustafa Khasraw; Simona Migliozzi; D Ryan Ormond; Sun Ha Paek; Erwin G Van Meir; Annemiek M E Walenkamp; Colin Watts; Tobias Weiss; Michael Weller; Karolina Palucka; Lucy F Stead; Laila M Poisson; Houtan Noushmehr; Antonio Iavarone; Roel G W Verhaak
Journal:  Cell       Date:  2022-05-31       Impact factor: 66.850

5.  Cancer Immunoediting in Gliomas: Recent Advances and Implications for Immunotherapy.

Authors:  Parth V Shah; Víctor A Arrieta; Catalina Lee-Chang; Adam M Sonabend
Journal:  J Cell Immunol       Date:  2020

6.  Tipping Cancer Cells Over the Edge: The Context-Dependent Cost of High Ploidy.

Authors:  Noemi Andor; Philipp M Altrock; Navami Jain; Ana P Gomes
Journal:  Cancer Res       Date:  2022-03-01       Impact factor: 13.312

Review 7.  Immune biology of glioma-associated macrophages and microglia: functional and therapeutic implications.

Authors:  Jun Wei; Peiwen Chen; Pravesh Gupta; Martina Ott; Daniel Zamler; Cynthia Kassab; Krishna P Bhat; Michael A Curran; John F de Groot; Amy B Heimberger
Journal:  Neuro Oncol       Date:  2020-02-20       Impact factor: 12.300

8.  Glioma immunoediting, a driver of tumor evolution, and the next battle for immunotherapy.

Authors:  Adam M Sonabend; Roger Stupp; Catalina Lee-Chang; Hideho Okada
Journal:  Oncotarget       Date:  2021-01-05

9.  A Prognostic Microenvironment-Related Immune Signature via ESTIMATE (PROMISE Model) Predicts Overall Survival of Patients With Glioma.

Authors:  Huaide Qiu; Yongqiang Li; Shupeng Cheng; Jiahui Li; Chuan He; Jianan Li
Journal:  Front Oncol       Date:  2020-12-07       Impact factor: 6.244

10.  The CXCL Family Contributes to Immunosuppressive Microenvironment in Gliomas and Assists in Gliomas Chemotherapy.

Authors:  Zeyu Wang; Yuze Liu; Yuyao Mo; Hao Zhang; Ziyu Dai; Xun Zhang; Weijie Ye; Hui Cao; Zhixiong Liu; Quan Cheng
Journal:  Front Immunol       Date:  2021-09-13       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.